Page 62 - Read Online

Méndez-Sánchez et al. Hepatoma Res 2020;6:5 I http://dx.doi.org/10.20517/2394-5079.2019.29 Page 13 of 13

77. Nag S, Qin J, Srivenugopal KS, Wang M, Zhang R. The MDM2-p53 pathway revisited. J Biomed Res 2013;27:254-71.
78. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010;10:51-7.
79. Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous
functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008;6:2853-68.
80. Nishida S, Hamada K, Nishino N, Fukushima D, Koyanagi R, et al. Efficacy of long-term rifaximin treatment for hepatic
encephalopathy in the Japanese. World J Hepatol 2019;11:531-41.
81. Kang SH, Lee YB, Lee JH, Nam JY, Chang Y, et al. Rifaximin treatment is associated with reduced risk of cirrhotic complications and
prolonged overall survival in patients experiencing hepatic encephalopathy. Aliment Pharmacol Ther 2017;46:845-55.
82. Elfert A, Abo Ali L, Soliman S, Ibrahim S, Abd-Elsalam S. Randomized-controlled trial of rifaximin versus norfloxacin for secondary
prophylaxis of spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol 2016;28:1450-4.
83. Kalambokis GN, Mouzaki A, Rodi M, Pappas K, Fotopoulos A, et al. Rifaximin improves systemic hemodynamics and renal function
in patients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol 2012;10:815-8.
84. Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, et al. Long-term administration of rifaximin improves
the prognosis of patients with decompensated alcoholic cirrhosis: rifaximin improves prognosis in cirrhosis. J Gastroenterol Hepatol
2013;28:450-5.
85. Shariff MIF, Tognarelli JM, Lewis MR, Want EJ, Mohamed FEZ, et al. Plasma lipid profiling in a rat model of hepatocellular
carcinoma: potential modulation through quinolone administration. J Clin Exp Hepatol 2015;5:286-94.
86. Ginés P, Rimola A, Planas R, Vargas V, Marco F, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis:
results of a double-blind, placebo-controlled trial. Hepatology 1990;12:716-24.
87. Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive
procedures and norfloxacin prophylaxis. Hepatology 2002;35:140-8.
88. Li J, Sung CYJ, Lee N, Ni Y, Pihlajamäki J, et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in
mice. Proc Natl Acad Sci U S A 2016;113:E1306-15.
89. Delaune V, Orci LA, Lacotte S, Peloso A, Schrenzel J, et al. Fecal microbiota transplantation: a promising strategy in preventing the
progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response. Expert Opin Biol Ther 2018;18:1061-71.